

CASE D0041 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Stephen C. D'Amico  
Type or print name

  
Signature

January 29, 2002  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 09/965,536

FILED: SEPTEMBER 26, 2001

FOR: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR,  
HGPRBMY5, EXPRESSED HIGHLY IN BRAIN AND OVARIAN  
TISSUES

**Attention: Box Missing Parts**

Assistant Commissioner for Patents  
Washington, DC 20231

RESPONSE TO NOTICE TO FILE MISSING PARTS

Sir:

The Notice to File Missing Parts of Application - Filing Date Granted dated December 4, 2001 (a copy of which is enclosed) has a shortened statutory time set to expire on February 4, 2002.

In response, applicants now submit an original fully executed Declaration and Power of Attorney. Please charge the \$130 surcharge fee under 37 CFR §1.16(e) to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.


Also enclosed is a paper copy of a Substitute Sequence Listing, a Substitute Computer Readable Form Copy thereof, and a Statement Verifying Identity of Above Copies.

The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

A duplicate copy of this letter is provided for charging purposes.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289  
Date: January 29, 2002

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/965,536	09/26/2001	John N. Feder	D0041NP

CONFIRMATION NO. 3734

## FORMALITIES LETTER



\*OC000000007152899\*

BRISTOL-MYERS SQUIBB COMPANY  
Route 206 and Provinceline Road  
Princeton, NJ 08540

Date Mailed: 12/04/2001

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

## Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.  
*A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.*
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

02/11/2002 NBERNE 00000045 193880 09965536

01 FC:105 130.00 CH

*A copy of this notice MUST be returned with the reply.*

A handwritten signature, possibly reading 'RM', is written above a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Stephen C. D'Amico  
Type or print name

  
Signature

January 29, 2002  
Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 09/965,536

FILED: SEPTEMBER 26, 2001

FOR: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR,  
HGPRBMY5, EXPRESSED HIGHLY IN BRAIN AND OVARIAN  
TISSUES

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING INCLUDING STATEMENT OF  
VERIFICATION IN RESPONSE TO MISSING PARTS NOTICE

Sir:

In response to the Notice to File Missing Parts of Application, the Sequence Listing has been amended to make it compliant with C.F.R. 1.822 and 1.823. Support for the amendments can be found in the specification, as originally filed, and the Sequence Listing, as originally submitted. Respectfully, no new matter has been added.

Applicants request the originally submitted paper copy and Computer Readable Form of the Sequence Listing be replaced with the paper copy and Computer Readable Form of the Substitute Sequence Listing submitted herewith. Applicants believe the Substitute Sequence Listing is in compliance with C.F.R. 1.822 and 1.823.

Applicants hereby provide a Computer Readable Form of the Substitute Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Substitute Paper Copy and the Substitute Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Respectfully submitted,



Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289  
Date: January 29, 2002